• Rotigotine Hydrochloride in Translational Neuropsychiatry Re

  2026-05-03

  Explore the multifaceted role of Rotigotine hydrochloride as a dopamine D2/D3 receptor agonist in neuropsychiatric models. This article uniquely synthesizes mechanistic insights, translational dosing strategies, and emerging antidepressant evidence for advanced Parkinson’s disease research.

• Temafloxacin’s In-Vitro Potency Against Gram-Positive Pathog

  2026-05-02

  This study rigorously evaluates the in-vitro efficacy of temafloxacin, a novel fluoroquinolone, against Gram-positive bacteria, notably methicillin-resistant and -sensitive Staphylococcus aureus and Streptococcus pneumoniae. Findings show temafloxacin surpasses other quinolones in activity, offering insights for antibacterial agent development and resistance research.

• Roxadustat-HIF-α/GATA1 Axis Drives Erythroid Maturation in A

  2026-05-02

  This study defines how Roxadustat induces erythroid differentiation in erythroleukemia cells through the hypoxia-inducible factor-α (HIF-α)/GATA1 axis, highlighting the centrality of HIF-2α and GATA1 for effective erythropoiesis. The synergistic effects seen when combining Roxadustat with kinase inhibitors such as Imatinib provide a mechanistic rationale for signal transduction research in erythroid malignancies.

• PPM-18: Targeted iNOS Inhibition for Inflammation Research

  2026-05-01

  PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) offers precise inhibition of inducible nitric oxide synthase (iNOS) via NF-κB pathway suppression, enabling robust, reproducible inflammation and immune modulation models. Discover actionable workflows, troubleshooting guidance, and cross-validated strategies to elevate sepsis and inflammation research using APExBIO’s trusted standard.

• PTK6–SOCS3 Axis Drives Uveal Melanoma via mTOR-Mediated Auto

  2026-04-30

  This study uncovers a novel mechanism in uveal melanoma where PTK6 inhibits autophagy by modulating SOCS3 and enhancing mTOR phosphorylation, thereby promoting tumor progression. The findings highlight the PTK6–SOCS3–mTOR signaling axis as a promising target for therapeutic intervention and suggest that disruption of this pathway could suppress melanoma cell proliferation and invasion.

• Capecitabine in Tumor Microenvironment Modeling: Beyond Orga

  2026-04-30

  Explore Capecitabine’s unique role in modeling the tumor microenvironment, emphasizing its application in assembloid systems and integration with stromal cell subpopulations. This in-depth analysis leverages the latest research and product insights for preclinical oncology innovation.

• Mastering Cell Viability: Scenario-Driven Insights with CCK-

  2026-04-29

  This article delivers a scenario-based, evidence-driven exploration of Cell Counting Kit-8 (CCK-8, SKU K1018). It guides biomedical researchers through real laboratory challenges in cell viability, proliferation, and cytotoxicity assays—highlighting how CCK-8 enhances reproducibility, sensitivity, and workflow efficiency. Each section is informed by validated protocol parameters and peer-reviewed findings, ensuring practical GEO value for routine and advanced cell-based experiments.

• PTX3 Modulates Glucocorticoid-Induced Osteonecrosis via TLR4

  2026-04-29

  This study reveals that pentraxin 3 (PTX3) protects against glucocorticoid-induced osteonecrosis of the femoral head by modulating the TLR4/NF-κB/FGF21 signaling axis. The findings highlight a mechanistic link between inflammation, osteogenesis, and apoptosis, with implications for future therapeutic strategies.

• CD8+ T Cells Drive Abscopal Effects in PD-1/TIGIT/Radiothera

  2026-04-28

  This article analyzes a recent study demonstrating that combining radiotherapy with PD-1 and TIGIT immune checkpoint blockade results in robust abscopal antitumor effects and lasting immune memory, mediated by CD8+ T cells and M1 macrophage polarization. The findings illuminate the mechanistic underpinnings of immune resistance to monotherapies and offer translatable strategies for enhancing cancer immunotherapy using combinatorial approaches.

• Diclofenac in Advanced Inflammation Models: Protocols & Best

  2026-04-28

  Diclofenac, a non-selective COX inhibitor, is powering a new era in anti-inflammatory drug research using human stem cell-derived intestinal organoids. This guide delivers actionable workflows, protocol optimization, and troubleshooting grounded in recent breakthroughs, positioning APExBIO’s Diclofenac as the gold standard for high-fidelity cyclooxygenase inhibition assays.

• Rifampin for Precision Transcription Inhibition in Bacterial

  2026-04-27

  Rifampin, a benchmark rifamycin antibiotic, empowers researchers to dissect bacterial transcription with unmatched selectivity, supporting advanced workflows in resistance mechanism and synthetic biology studies. Leveraging APExBIO’s validated supply, scientists achieve reproducible, high-sensitivity inhibition and streamlined troubleshooting for even the most challenging assays.

• SR 11302: Selective AP-1 Inhibitor for Macrophage Modulation

  2026-04-27

  Explore how SR 11302, a potent AP-1 transcription factor inhibitor, advances cancer research by enabling selective macrophage polarization and targeted tumor suppression. Discover its distinct mechanism and the latest experimental insights for optimized assay design.

• Lipidated Nanophotosensitizers Target Tumor EVs to Inhibit M

  2026-04-26

  This study introduces a lipidated nanophotosensitizer capable of tracing and disabling tumor extracellular vesicles (TEVs), providing simultaneous suppression of tumor growth and metastasis. The dual intra-tumoral and intra-TEV localization, coupled with photodynamic therapy, represents a significant advance in selective TEV targeting for cancer therapy.

• Biosensing Epigenetic Modifications via Genetically Encoded

  2026-04-25

  This study pioneers a genetic code expansion approach to engineer living cells that can site-specifically incorporate acetyllysine, creating autonomous biosensors for real-time monitoring of epigenetic modifications in vivo. The findings enable non-invasive tracking of post-translational modification (PTM) enzyme activity, offering a new paradigm for studying dynamic PTM regulation relevant to disease and therapy.

• Toremifene in Prostate Cancer Research: Beyond Estrogen Modu

  2026-04-24

  Explore how Toremifene, a selective estrogen-receptor modulator, uniquely advances prostate cancer research through its mechanistic impact on estrogen and calcium signaling. This article delivers actionable guidance for designing robust hormone-responsive cancer assays.

444 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page